1887
Surveillance Open Access
Like 0

Abstract

Background

Surveillance of tuberculosis (TB) treatment outcome, for which reporting has been mandatory in France since 2007, is a key component of TB control.

Aim

We aimed to present surveillance data for non-multidrug-resistant (MDR) cases reported between 2008 and 2014, and identify factors associated with potentially unfavourable treatment outcome.

Methods

Patients were classified according to their treatment outcome 12 months after beginning treatment. Poisson regression with a robust error variance was used to investigate factors associated with potentially unfavourable treatment outcome. Missing data were handled using multiple imputation.

Results

A total of 22,526 cases were analysed for treatment outcome. Information available on treatment outcome increased between 2008 (60%) and 2014 (71%) (p < 0.001). During this period, 74.1% of cases completed treatment, increasing from 73.0% in 2008 to 76.9% in 2014 (p < 0.001). This proportion was 74.0% in culture-positive pulmonary cases. Overall, 19.8% of cases had a potentially unfavourable outcome, including lost-to-follow-up, transferred out, still on treatment, death related to TB and interrupted treatment. Potentially unfavourable outcome was significantly associated with TB severity, residing in congregate settings, homelessness, being a smear-positive pulmonary case, being born abroad and residing in France for < 2 years, history of previous anti-TB treatment and age > 85 years.

Conclusion

Monitoring of treatment outcome is improving over time. The increase in treatment completion over time suggests improved case management. However, treatment outcome monitoring needs to be strengthened in cases belonging to population groups where the percentage of unfavourable outcome is the highest and in cases where surveillance data shows poorer documented follow-up.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2020.25.4.1900191
2020-01-30
2020-09-28
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2020.25.4.1900191
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/25/4/eurosurv-25-4-4.html?itemId=/content/10.2807/1560-7917.ES.2020.25.4.1900191&mimeType=html&fmt=ahah

References

  1. World Health Organization (WHO). Global tuberculosis report, 2019. Geneva: WHO; 2019. [Accessed 15 Dec 2019]. Available from: https://www.who.int/tb/publications/global_report/en/
  2. World Health Organization Regional Office for Europe (WHO/Europe)/European Centre for Disease Prevention and Control (ECDC). Tuberculosis surveillance and monitoring in Europe 2019. Copenhagen: WHO/Europe; 2019. Available from: https://ecdc.europa.eu/en/tuberculosis/surveillance-and-disease-data/annual-tb-surveillance
  3. Santé publique France. Tuberculose. Données épidémiologiques. [Tuberculosis. Epidemiological data]. Saint-Maurice: Santé publique France; 2019. [Accessed 15 Apr 2019]. French. Available from: http://invs.santepubliquefrance.fr/Dossiers-thematiques/Maladies-infectieuses/Infections-respiratoires/Tuberculose/Donnees-epidemiologiques
  4. TB CARE I. International standards for tuberculosis care. 3rd edition. The Hague: TB CARE I; 2014. Available from: http://www.who.int/tb/publications/ISTC_3rdEd.pdf
  5. World Health Organization (WHO). Forty-fourth World Health Assembly, Resolutions and Decisions. Resolution WHA44.8. Geneva: WHO; 1991. [Accessed 13 Nov 2017]. Available from: https://www.who.int/tb/publications/tbresolution_wha44_8_1991.pdf?ua=1/
  6. World Health Organization (WHO). Implementing the end TB strategy: the essentials. Geneva: WHO; 2015. Available from: http://www.who.int/tb/publications/2015/end_tb_essential.pdf?ua=1
  7. Antoine D, Che D. Les issues de traitement des cas de tuberculose déclarés en France en 2008. [Treatment outcomes of tuberculosis cases notified in France in 2008]. Bull Epidemiol Hebd (Paris). 2011;(32):345-8. French.
  8. Antoine D, Che D. Treatment outcome monitoring of pulmonary tuberculosis cases notified in France in 2009. Euro Surveill. 2013;18(12):20434. PMID: 23557945 
  9. World Health Organisation (WHO). Definitions and reporting framework for tuberculosis, 2013 revision, updated on December 2014. Geneva: WHO; 2013. Available from: http://www.who.int/tb/publications/definitions/en/
  10. Rieder HL, Watson JM, Raviglione MC, Forssbohm M, Migliori GB, Schwoebel V, et al. Surveillance of tuberculosis in Europe. Working Group of the World Health Organization (WHO) and the European Region of the International Union Against Tuberculosis and Lung Disease (IUATLD) for uniform reporting on tuberculosis cases. Eur Respir J. 1996;9(5):1097-104.  https://doi.org/10.1183/09031936.96.09051097  PMID: 8793477 
  11. European Centre for Disease Prevention and Control (ECDC)/WHO Regional Office for Europe (WHO/Europe). Tuberculosis surveillance and monitoring in Europe 2012. Stockholm: ECDC; 2012. Available from: https://ecdc.europa.eu/en/publications-data/tuberculosis-surveillance-and-monitoring-europe-2012
  12. Veen J, Raviglione M, Rieder HL, Migliori GB, Graf P, Grzemska M, et al. Standardized tuberculosis treatment outcome monitoring in Europe. Recommendations of a Working Group of the World Health Organization (WHO) and the European Region of the International Union Against Tuberculosis and Lung Disease (IUATLD) for uniform reporting by cohort analysis of treatment outcome in tuberculosis patients. Eur Respir J. 1998;12(2):505-10.  https://doi.org/10.1183/09031936.98.12020505  PMID: 9727811 
  13. World Health Organization (WHO). WHO treatment guidelines for drug-resistant tuberculosis. 2016 update. October 2016 revision. Geneva: WHO; 2016. Available from: http://apps.who.int/iris/bitstream/10665/250125/1/9789241549639-eng.pdf
  14. Karo B, Hauer B, Hollo V, van der Werf MJ, Fiebig L, Haas W. Tuberculosis treatment outcome in the European Union and European Economic Area: an analysis of surveillance data from 2002-2011. Euro Surveill. 2015;20(49):30087.  https://doi.org/10.2807/1560-7917.ES.2015.20.49.30087  PMID: 26676247 
  15. White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. Stat Med. 2011;30(4):377-99.  https://doi.org/10.1002/sim.4067  PMID: 21225900 
  16. Sterne JA, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ. 2009;338(jun29 1):b2393.  https://doi.org/10.1136/bmj.b2393  PMID: 19564179 
  17. Graham JW, Olchowski AE, Gilreath TD. How many imputations are really needed? Some practical clarifications of multiple imputation theory. Prev Sci. 2007;8(3):206-13.  https://doi.org/10.1007/s11121-007-0070-9  PMID: 17549635 
  18. Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159(7):702-6.  https://doi.org/10.1093/aje/kwh090  PMID: 15033648 
  19. Little RJA, Rubin DB. Statistical Analysis with Missing Data. 2 ed. Hoboken, New Jersey: John Wiley & Sons: 2002. 381 p.
  20. Royston P, Ambler G, Sauerbrei W. The use of fractional polynomials to model continuous risk variables in epidemiology. Int J Epidemiol. 1999;28(5):964-74.  https://doi.org/10.1093/ije/28.5.964  PMID: 10597998 
  21. Guthmann JP, Ait Belghiti F, Levy Bruhl D. Épidémiologie de la tuberculose en France en 2015. Impact de la suspension de l’obligation vaccinale BCG sur la tuberculose de l’enfant, 2007-2015. Numéro thématique. Journée mondiale de lutte contre la tuberculose, 24 mars 2017. [Epidemiology of tuberculosis in France in 2015. Impact of the suspension of the BCG vaccination obligation on childhood tuberculosis, 2007-2015. Thematic issue. World TB Day, 24 March 2017]. Bull Epidemiol Hebd (Paris). 2017;(7):116-26. French.
  22. van Hest R, Ködmön C, Verver S, Erkens CG, Straetemans M, Manissero D, et al. Tuberculosis treatment outcome monitoring in European Union countries: systematic review. Eur Respir J. 2013;41(3):635-43.  https://doi.org/10.1183/09031936.00030612  PMID: 22790913 
  23. Cegolon L, Maguire H, Mastrangelo G, Carless J, Kruijshaar ME, Verlander NQ. Predictors of failure to complete tuberculosis treatment in London, 2003-2006. Int J Tuberc Lung Dis. 2010;14(11):1411-7. PMID: 20937180 
  24. Ditah IC, Reacher M, Palmer C, Watson JM, Innes J, Kruijshaar ME, et al. Monitoring tuberculosis treatment outcome: analysis of national surveillance data from a clinical perspective. Thorax. 2008;63(5):440-6.  https://doi.org/10.1136/thx.2006.073916  PMID: 17615085 
  25. Millett ER, Noel D, Mangtani P, Abubakar I, Kruijshaar ME. Factors associated with being lost to follow-up before completing tuberculosis treatment: analysis of surveillance data. Epidemiol Infect. 2013;141(6):1223-31.  https://doi.org/10.1017/S095026881200163X  PMID: 22846385 
  26. European Monitoring Centre for Drugs and Drug Addictions (EMCDDA). Selected issue 2: A gender perspective on drug use and responding to drug problems. Lisbon: EMCDDA; 2006.Available from: http://www.emcdda.europa.eu/system/files/publications/426/sel2006_2-en_69712.pdf
  27. Diel R, Niemann S. Outcome of tuberculosis treatment in Hamburg: a survey, 1997-2001. Int J Tuberc Lung Dis. 2003;7(2):124-31. PMID: 12588012 
  28. Girard D, Antoine D, Che D. Epidemiology of pulmonary tuberculosis in France. Can the hospital discharge database be a reliable source of information? Med Mal Infect. 2014;44(11-12):509-14.  https://doi.org/10.1016/j.medmal.2014.10.002  PMID: 25455077 
  29. Wulff JN, Ejlskov L. Multiple imputation by chained equations in praxis: Guidelines and review. Electron J Bus Res Methods. 2017;15(1):41-56.
  30. Masjedi MR, Hosseini M, Aryanpur M, Mortaz E, Tabarsi P, Soori H, et al. The effects of smoking on treatment outcome in patients newly diagnosed with pulmonary tuberculosis. Int J Tuberc Lung Dis. 2017;21(3):351-6.  https://doi.org/10.5588/ijtld.16.0513  PMID: 28225348 
  31. Jiménez-Corona ME, Cruz-Hervert LP, García-García L, Ferreyra-Reyes L, Delgado-Sánchez G, Bobadilla-Del-Valle M, et al. Association of diabetes and tuberculosis: impact on treatment and post-treatment outcomes. Thorax. 2013;68(3):214-20.  https://doi.org/10.1136/thoraxjnl-2012-201756  PMID: 23250998 
  32. Lee PH, Fu H, Lee MR, Magee M, Lin HH. Tuberculosis and diabetes in low and moderate tuberculosis incidence countries. Int J Tuberc Lung Dis. 2018;22(1):7-16.  https://doi.org/10.5588/ijtld.17.0329  PMID: 29297421 
  33. Karo B, Krause G, Hollo V, van der Werf MJ, Castell S, Hamouda O, et al. Impact of HIV infection on treatment outcome of tuberculosis in Europe. AIDS. 2016;30(7):1089-98.  https://doi.org/10.1097/QAD.0000000000001016  PMID: 26752278 
/content/10.2807/1560-7917.ES.2020.25.4.1900191
Loading

Data & Media loading...

Comment has been disabled for this content
Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error